Clinical Trials Search
Clinical Trial 18431
Study Type: Screening
Phase of Study: NA
- Benjamin Creelan
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
The purpose of this Screening Study is to perform two tests to test for proteins in potential participant's body to see if they might be able to participate in a Treatment Study. There is no treatment associated with this Screening Study. The results of this screening study will help study doctors to determine whether potential participants are eligible to move forward with screening for a changed T cell treatment in a Treatment Study.
This protocol supports enrollment to both the MAGE-A10 trial (pending SRC submission) and the NYESO1 trial (MCC 18342, SRC approved). In the future it may be expanded for additional trials planned by this sponsor.